Mestinon (Pyridostigmine Bromide)

Pyridostigmine works by reversibly inhibiting the enzyme acetylcholinesterase at the neuromuscular junction. This inhibition raises the level of acetylcholine in the synaptic cleft, allowing more frequent stimulation of nicotinic receptors on skeletal muscle and thereby improving muscle contraction.

The appropriate dose of Mestinon is individualized by the prescribing clinician based on the severity of the condition, patient weight, renal function, and response to therapy. Patients should follow the dosage instructions provided by their healthcare professional and not adjust the dose on their own.

Safety data for pyridostigmine in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their physician.

To order Mestinon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Mestinon (pyridostigmine) is a symptomatic anticholinesterase that improves neuromuscular transmission, whereas immunosuppressants such as azathioprine or corticosteroids target the underlying autoimmune process. Compared with older agents like neostigmine, pyridostigmine has a longer duration of action and a more favorable side‑effect profile, making it a first‑line oral therapy.

Mestinon should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from excess moisture, direct sunlight and heat sources to maintain stability and potency throughout its shelf life.

Mestinon is taken orally, usually with a glass of water. It can be administered with or without food, but taking it with meals may reduce gastrointestinal upset. The tablet should be swallowed whole and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious risks include cholinergic crisis, which can present as severe muscle weakness, respiratory failure, and bradycardia, as well as bronchospasm and cardiac arrhythmias. Patients should seek immediate medical attention if they experience sudden difficulty breathing, fainting, or a rapid decline in muscle strength.

Mestinon is contraindicated in patients with known hypersensitivity to pyridostigmine or any component of the formulation. Caution is advised for individuals with severe asthma, significant renal impairment, or those taking potent anticholinergic medications that could negate its effect.